The following clinicians contributed to this briefing:
Prof Rob Stein, consultant, University College London Hospitals NHS Foundation Trust; chief investigator of the OPTIMA trial, which seeks to investigate the ability of tumour gene expression tests to predict chemotherapy sensitivity for ER-positive HER2-negative breast cancer. There are no plans to assess the MammaTyper technology in the main OPTIMA study. However, with the collaboration of the vendor it was one of 6 related technologies evaluated in the OPTIMA feasibility study. That data is published in the formal report of OPTIMA-prelim and in Bartlett et al. 2016, which is referenced in the briefing document.
Dr Roger Hunt, consultant histopathologist, Manchester University NHS Foundation Trust.
Mr Simon Pain, consultant breast surgeon, Norfolk and Norwich University Hospitals NHS Trust, sat on advisory boards organised by Genomic Health to discuss use of the Oncotype DX test; gave talks to healthcare professionals about this test. He received honoraria for this work.